# A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer

> **NCT00937560** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 190 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Paclitaxel
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00937560
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06-25
- **Primary completion:** 2012-07-31
- **Final completion:** 2013-07-01
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00937560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00937560, "A Study of First Line Treatment With Avastin (Bevacizumab) in Combination With Carboplatin and Weekly Paclitaxel in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00937560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*